You are here

  • Home
  • Archive
  • Volume 27, Issue 6
  • Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

Article metrics

Article menu
Download PDFPDF
Cervical Cancer
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

 

Online download statistics by month:

Online download statistics by month: February 2019 to September 2024

AbstractFullPdf
Feb 2019600
Mar 20194402
Apr 20193001
May 20195200
Jun 20193000
Jul 20198704
Aug 20193500
Sep 20193400
Oct 20194101
Nov 20195201
Dec 20194300
Jan 20206702
Feb 20207300
Mar 20207200
Apr 20205800
May 20209002
Jun 20205400
Jul 20207901
Aug 202011507
Sep 20207603
Oct 20203200
Nov 20204001
Dec 20203002
Jan 20215303
Feb 20215403
Mar 20218800
Apr 20219900
May 20215300
Jun 20211001
Jul 2021700
Aug 20211300
Sep 20211102
Oct 20218401
Nov 202110401
Dec 202111702
Jan 202211202
Feb 202216600
Mar 202213702
Apr 202215701
May 202223202
Jun 202213500
Jul 202210700
Aug 202212501
Sep 202218302
Oct 202219500
Nov 202220101
Dec 202214502
Jan 202314100
Feb 202322500
Mar 202312701
Apr 202312400
May 202315100
Jun 202312900
Jul 202314500
Aug 202315501
Sep 202313902
Oct 202310100
Nov 20237400
Dec 202310000
Jan 20249000
Feb 20246200
Mar 20244600
Apr 20248800
May 20243600
Jun 20247901
Jul 20249000
Aug 202411400
Sep 20241600
Total6060058